Loading
A phase 3 trial of Zanidatamab, Trastuzumab, Eribulin in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT06435429 by Jazz Pharmaceuticals, with 550 participants planned, started 2024-08-13 and due to reach its primary completion in 2028-04-28. Interventions recorded: Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine. Conditions listed: Metastatic HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies, Trastuzumab.
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine.
Shares Trastuzumab, Capecitabine, Gemcitabine, HER2-positive breast cancer.